RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway - PubMed (original) (raw)

. 2016 Jul 1;76(13):3813-25.

doi: 10.1158/0008-5472.CAN-15-2882. Epub 2016 Jun 20.

Xing-Xing Lu 1, Wen-Juan Gan 2, Xiu-Ming Li 1, Xiao-Shun He 2, Shen Zhang 1, Qing-Hua Ji 1, Feng Zhou 1, Yue Cao 1, Jing-Ru Wang 1, Jian-Ming Li 3, Hua Wu 3

Affiliations

• PMID: 27325643
• DOI: 10.1158/0008-5472.CAN-15-2882

RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway

Peng-Da Guo et al. Cancer Res. 2016.

Abstract

The Hippo-Yap pathway conveys oncogenic signals, but its regulation during cancer development is not well understood. Here, we identify the nuclear receptor RARγ as a regulator of the Hippo-Yap pathway in colorectal tumorigenesis and metastasis. RARγ is downregulated in human colorectal cancer tissues, where its expression correlates inversely with tumor size, TNM stage, and distant metastasis. Functional studies established that silencing of RARγ drove colorectal cancer cell growth, invasion, and metastatic properties both in vitro and in vivo Mechanistically, RARγ controlled Hippo-Yap signaling to inhibit colorectal cancer development, acting to promote phosphorylation and binding of Lats1 to its transcriptional coactivator Yap and thereby inactivating Yap target gene expression. In clinical specimens, RARγ expression correlated with overall survival outcomes and expression of critical Hippo-Yap pathway effector molecules in colorectal cancer patients. Collectively, our results defined RARγ as tumor suppressor in colorectal cancer that acts by restricting oncogenic signaling by the Hippo-Yap pathway, with potential implications for new approaches to colorectal cancer therapy. Cancer Res; 76(13); 3813-25. ©2016 AACR.

©2016 American Association for Cancer Research.

PubMed Disclaimer

Similar articles

• Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
  Si Y, Ji X, Cao X, Dai X, Xu L, Zhao H, Guo X, Yan H, Zhang H, Zhu C, Zhou Q, Tang M, Xia Z, Li L, Cong YS, Ye S, Liang T, Feng XH, Zhao B. Si Y, et al. Cancer Res. 2017 Sep 15;77(18):4868-4880. doi: 10.1158/0008-5472.CAN-17-0391. Epub 2017 Jul 28. Cancer Res. 2017. PMID: 28754671
• A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling.
  Zheng X, Chen L, Zhou Y, Wang Q, Zheng Z, Xu B, Wu C, Zhou Q, Hu W, Wu C, Jiang J. Zheng X, et al. Mol Cancer. 2019 Mar 29;18(1):47. doi: 10.1186/s12943-019-1010-6. Mol Cancer. 2019. PMID: 30925892 Free PMC article.
• The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway.
  Salah Z, Itzhaki E, Aqeilan RI. Salah Z, et al. Oncotarget. 2014 Nov 15;5(21):10886-900. doi: 10.18632/oncotarget.2540. Oncotarget. 2014. PMID: 25350971 Free PMC article.
• The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy.
  Wang H, Du YC, Zhou XJ, Liu H, Tang SC. Wang H, et al. Cancer Metastasis Rev. 2014 Mar;33(1):173-81. doi: 10.1007/s10555-013-9463-3. Cancer Metastasis Rev. 2014. PMID: 24346160 Review.
• Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.
  Ferraiuolo M, Verduci L, Blandino G, Strano S. Ferraiuolo M, et al. Int J Mol Sci. 2017 May 3;18(5):961. doi: 10.3390/ijms18050961. Int J Mol Sci. 2017. PMID: 28467351 Free PMC article. Review.

Cited by

• YAP/TAZ Activation as a Target for Treating Metastatic Cancer.
  Warren JSA, Xiao Y, Lamar JM. Warren JSA, et al. Cancers (Basel). 2018 Apr 10;10(4):115. doi: 10.3390/cancers10040115. Cancers (Basel). 2018. PMID: 29642615 Free PMC article. Review.
• Orphan nuclear receptor Nur77 inhibits poly (I:C)-triggered acute liver inflammation by inducing the ubiquitin-editing enzyme A20.
  Li XM, Yang TY, He XS, Wang JR, Gan WJ, Zhang S, Li JM, Wu H. Li XM, et al. Oncotarget. 2017 May 9;8(37):61025-61035. doi: 10.18632/oncotarget.17731. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 28977843 Free PMC article.
• Oncogenic potential of BEST4 in colorectal cancer via activation of PI3K/Akt signaling.
  He XS, Ye WL, Zhang YJ, Yang XQ, Liu F, Wang JR, Ding XL, Yang Y, Zhang RN, Zhao YY, Bi HX, Guo LC, Gan WJ, Wu H. He XS, et al. Oncogene. 2022 Feb;41(8):1166-1177. doi: 10.1038/s41388-021-02160-2. Epub 2022 Jan 21. Oncogene. 2022. PMID: 35058597
• YAP promotes epithelial mesenchymal transition by upregulating Slug expression in human colorectal cancer cells.
  Cheng D, Jin L, Chen Y, Xi X, Guo Y. Cheng D, et al. Int J Clin Exp Pathol. 2020 Apr 1;13(4):701-710. eCollection 2020. Int J Clin Exp Pathol. 2020. PMID: 32355518 Free PMC article.
• The Hippo signalling pathway and its implications in human health and diseases.
  Fu M, Hu Y, Lan T, Guan KL, Luo T, Luo M. Fu M, et al. Signal Transduct Target Ther. 2022 Nov 8;7(1):376. doi: 10.1038/s41392-022-01191-9. Signal Transduct Target Ther. 2022. PMID: 36347846 Free PMC article. Review.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information